



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re:	) Customer No. 47670
U.S. Patent Application	)
	) Attorney Docket: 017191.0049
Applicant: Michael J. Pugia, et al.	)
Serial No. 10/574,862	)
	)
Filed: April 6, 2006	)
	)
For: <b>Monoclonal Antibodies for Detection of</b>	)
<b>Urinary Trypsin Inhibitors</b>	)
	)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Statement Under 37 C.F.R. 1.804(b)

A copy of a deposit receipt from ATCC is enclosed. The three murine hybridoma cell lines identified in the receipt are those identified in the subject patent application, as corroborated by the enclosed statement by the first-named inventor.

Respectfully submitted,

3/8/07  
Date

Harold N. Wells  
Harold Wells  
Reg. No. 26,044  
Kelley Drye & Warren LLP  
333 West Wacker Drive, Suite 2600  
Chicago, IL 60606  
(312) 857-7070  
(312) 857-7095 (Fax)

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF  
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3  
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

Bayer Healthcare LLC

ATTN: David Brock

1884 Miles Ave.

Elkhart, IN 46514

Deposited on Behalf of: Bayer Healthcare LLC

## Identification Reference by Depositor:

Murine Hybridoma Cell Line: 420-5D11.5G8-1E4

Murine Hybridoma Cell Line: 421-5G8.1A8.5C1

Murine Hybridoma Cell Line: 421-3G5.4C5.3B6

## Patent Deposit Designation

PTA-7744

PTA-7745

PTA-7746

The deposit was accompanied by: X a scientific description    a proposed taxonomic description indicated above.

The deposit was received, July 28, 2006 by this International Depository Authority and has been accepted.

AT YOUR REQUEST: X We will inform you of requests for the strain for 30 years.

The strain will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strain, and ATCC is instructed by the United States Patent &amp; Trademark Office or the depositor to release said strain.

If the culture should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace it with living culture of the same.

The strain will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the culture cited above was tested, August 14, 2006. On that date, the culture was viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:

Dee Bishop, ATCC Patent Depository

Date: August 16, 2006

cc: Bayer Healthcare LLC Kevin Stein



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: ) Customer No. 47670  
U.S. Patent Application )  
Applicant: Michael J. Pugia, et al. ) Attorney Docket: 017191.0049  
Serial No. 10/574,862 )  
Filed: April 6, 2006 )  
For: **Monoclonal Antibodies for Detection of** )  
**Urinary Trypsin Inhibitors** )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Statement Under 37 C.F.R. 1.804(b)

The three murine hybridoma cell lines designated as PTA-7744, 7745 and 7746 in the accompanying ATCC deposit receipt were deposited by David Brock at my direction. These three cell lines are those identified in the subject application by the reference numbers provided by the Depositor.

Respectfully submitted,

Mar 1 07  
Date

Michael J. Pugia  
Michael J. Pugia, Ph.D.